低分子イノベーターAPI CDMOの市場規模、シェア、動向分析レポート：段階タイプ別、顧客タイプ別、治療領域別、地域別、セグメント予測、2024年～2030年

低分子イノベーターAPI CDMO市場の成長と動向：

Grand View Research, Inc.の最新レポートによると、低分子イノベーターAPI CDMOの世界市場規模は、2024年から2030年にかけてCAGR 6.53%を記録し、2030年までに471億4,000万米ドルに達すると予測されています。

製薬企業のアウトソーシング傾向の高まり、低分子医薬品の需要増加、臨床試験件数の急増が市場にプラスの影響を与えると予測されています。製薬セクターにおけるCDMOの利用拡大には様々な理由があり、中でも費用対効果が顕著な要因となっています。アウトソーシングは、高価なインフラや設備投資の必要性を回避して経費を削減する製薬会社の効率的な戦略として浮上しています。CDMOは、必要な専門知識とインフラを提供し、財政的に賢明な方法で医薬品開発・製造サービスを提供します。

さらに、効率性の向上も医薬品アウトソーシングの重要な推進力となっています。新薬の市場投入を急ぐよう製薬会社にプレッシャーがかかる中、アウトソーシングは医薬品開発プロセスを加速させるソリューションとして浮上しています。CDMOは、その専門知識、経験、最先端の設備を活用し、高品質な医薬品の迅速かつ効率的な生産を促進し、製薬企業が開発スケジュールを遵守することを可能にします。加えて、新規治療薬や希少疾病用医薬品の流入が増加し、承認済み製品の収益が高まっていることから、先進的なインフラや専門知識を利用するためにCDMOを選択する製薬企業もあります。さらに、CDMOの継続的な技術進歩は、医療業界における技術革新、効率性、規制遵守への高まる要求に応える革新的な低分子原薬を提供しています。

企業が先端技術を採用することで、医薬品開発、製造プロセス、生産性が向上します。製薬業界における新規低分子イノベーターAPIに対する需要の増加は、商業CDMOの能力拡大を促しており、これが市場成長を後押しすると予想されます。例えば、2023年8月、アステックスはMSDとの間で、がん治療用の腫瘍抑制タンパク質を持つ低分子化合物候補を分類するための共同研究＆ライセンス契約を発表しました。この契約に基づき、同社はフラグメントベースの創薬プラットフォームを使用して化合物を開発し、前臨床開発・最適化のための主要化合物をMSDに提供します。

低分子イノベーターAPI CDMO市場レポートハイライト

• 2023年のシェアは54.68%で、臨床段階セグメントが市場を独占しました。このセグメントの成長は、多様な製剤の臨床試験（第I～III相）活動の活発化、低分子開発パイプラインの拡大、専門知識の利用可能性の増加、治験薬の時間短縮とコスト効率化、イノベーションに起因しています。さらに、医薬品開発のための資金調達が増加していることも、同分野の成長を後押ししています。
• 顧客タイプ別に見ると、医薬品セグメントは、先端医薬品開発のための医薬品研究開発の急速な進歩により、2023年に最大のシェアを占めました。また、さまざまな治療法の進歩により、製薬企業のCDMOへの関心は、多数の疾患を治療するための新規低分子イノベーターAPI医薬品の開発に移っています。
• がん治療領域セグメントは市場を独占し、2023年には42.25%のシェアを占めました。同分野の成長を牽引しているのは、世界のがん罹患率の増加です。また、革新的な低分子イノベーターAPIに対する需要の高まり、標的治療の進歩、がん治療薬の革新に対する需要が、がん治療分野のセグメントを牽引する要因となっています。
• アジア太平洋地域は、慢性疾患の有病率の増加、低分子原薬とCDMOサービスの需要、医療インフラの改善により、2023年には41.53%のシェアで市場を独占しました。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 低分子イノベーターAPI CDMO市場の変数、動向、範囲

• 市場系統の見通し
• 市場力学
• テクノロジーの情勢
• フェーズ別・地域別の臨床試験総数（2021年～2023年）
• 低分子イノベーターAPI CDMO市場：分析ツール
• COVID-19による低分子イノベーターAPI CDMO市場への影響
• COVID-19の影響分析

第4章 低分子イノベーターAPI CDMO市場：段階タイプの推定・動向分析

• セグメントダッシュボード
• 世界の低分子イノベーターAPI CDMO市場の変動分析
• 世界の低分子イノベーターAPI CDMO市場規模と動向分析、段階タイプ別、2018年～2030年

第5章 低分子イノベーターAPI CDMO市場：顧客タイプの推定・動向分析

• セグメントダッシュボード
• 世界の低分子イノベーターAPI CDMO市場の変動分析
• 世界の低分子イノベーターAPI CDMO市場規模と動向分析、顧客タイプ別、2018年～2030年

第6章 低分子イノベーターAPI CDMO市場：治療領域の推定・動向分析

• 定義と範囲
• 治療領域の市場シェア、2023年と2030年
• セグメントダッシュボード
• 世界の低分子イノベーターAPI CDMO市場の変動分析
• 世界の低分子イノベーターAPI CDMO市場規模と動向分析、治療領域別、2018年～2030年

第7章 低分子イノベーターAPI CDMO市場：地域の推定・動向分析

• 地域の市場ダッシュボード
• 世界の地域の市場スナップショット
• 市場規模、予測動向分析、2018年～2030年：
• 北米
• 欧州
• アジア太平洋地域
• ラテンアメリカ
• 中東・アフリカ

第8章 競合情勢

• 市場参入企業の分類
• サービスヒートマップ分析（プレイヤー同士の比較分析）
• 企業プロファイル
• ベンダー情勢
  • Key company market share analysis, 2023
  • Lonza Group Ltd.
  • Novo Holdings（Catalent, Inc.）
  • Thermo Fisher Scientific, Inc.
  • Siegfried Holding AG
  • Recipharm AB
  • CordenPharma International
  • Samsung Biologics
  • Labcorp
  • Ajinomoto Bio-Pharma Services
  • Piramal Pharma Solutions
  • Jubilant Life Sciences（Jubilant Biosys Limited）
  • WuXi AppTec Co., Ltd.

List of Tables

• Table 1 List of abbreviation
• Table 2 North America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
• Table 3 North America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 4 North America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 5 North America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 6 U.S. Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 7 U.S. Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 8 U.S. Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 9 Canada Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 10 Canada Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 11 Canada Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 12 Europe Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
• Table 13 Europe Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 14 Europe Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 15 Europe Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 16 UK Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 17 UK Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 18 UK Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 19 Germany Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 20 Germany Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 21 Germany Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 22 France Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 23 France Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 24 France Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 25 Italy Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 26 Italy Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 27 Italy Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 28 Spain Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 29 Spain Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 30 Spain Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 31 Denmark Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 32 Denmark Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 33 Denmark Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 34 Sweden Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 35 Sweden Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 36 Sweden Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 37 Norway Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 38 Norway Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 39 Norway Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 40 Asia Pacific Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
• Table 41 Asia Pacific Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 42 Asia Pacific Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 43 Asia Pacific Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 44 China Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 45 China Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 46 China Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 47 Japan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 48 Japan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 49 Japan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 50 India Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 51 India Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 52 India Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 53 Australia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 54 Australia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 55 Australia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 56 South Korea Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 57 South Korea Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 58 South Korea Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 59 Thailand Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 60 Thailand Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 61 Thailand Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 62 Taiwan Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 63 Taiwan Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 64 Taiwan Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 65 Latin America Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
• Table 66 Latin America Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 67 Latin America Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 68 Latin America Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 69 Brazil Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 70 Brazil Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 71 Brazil Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 72 Mexico Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 73 Mexico Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 74 Mexico Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 75 Argentina Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 76 Argentina Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 77 Argentina Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 78 MEA Small Molecule Innovator API CDMO market, by region, 2018 - 2030 (USD Million)
• Table 79 MEA Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 80 MEA Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 81 MEA Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 82 South Africa Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 83 South Africa Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 84 South Africa Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 85 Saudi Arabia Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 86 Saudi Arabia Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 87 Saudi Arabia Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 88 UAE Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 89 UAE Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 90 UAE Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 91 Kuwait Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 92 Kuwait Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 93 Kuwait Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
• Table 94 Israel Small Molecule Innovator API CDMO market, by Stage Type, 2018 - 2030 (USD Million)
• Table 95 Israel Small Molecule Innovator API CDMO market, by Customer Type, 2018 - 2030 (USD Million)
• Table 96 Israel Small Molecule Innovator API CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)

List of Figures

• Fig. 1 Small molecule innovator API CDMO market segmentation
• Fig. 2 Market research process
• Fig. 3 Information procurement
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Market formulation & validation
• Fig. 7 Commodity flow analysis
• Fig. 8 Value-Chain-Based Sizing & Forecasting
• Fig. 9 QFD model sizing & forecasting
• Fig. 10 Bottom-up approach
• Fig. 11 Market snapshot
• Fig. 12 Segment snapshot
• Fig. 13 Segment snapshot
• Fig. 14 Competitive landscape snapshot
• Fig. 15 Parent market outlook, 2023(USD Million)
• Fig. 16 Ancillary market outlook, 2023 (USD Million)
• Fig. 17 Small molecule innovator API CDMO market dynamics
• Fig. 18 FDA's novel drug approvals in 2023
• Fig. 19 Percentage of clinical trials by major countries in North America
• Fig. 20 Percentage of clinical trials by major countries in Europe
• Fig. 21 Percentage of clinical trials by major countries in Asia Pacific
• Fig. 22 Percentage of clinical trials by major countries in Latin America
• Fig. 23 Percentage of clinical trials by major countries in Middle East & Africa
• Fig. 24 Porter's five forces analysis
• Fig. 25 Small molecule innovator API CDMO market: PESTEL analysis
• Fig. 26 Small molecule innovator API CDMO market: Stage Type outlook and key takeaways
• Fig. 27 Small molecule innovator API CDMO market: Stage type movement analysis
• Fig. 28 Preclinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 29 Clinical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 30 Phase I small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 31 Phase II small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Phase III small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 33 Commercial small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Small molecule innovator API CDMO market: Customer type outlook and key takeaways
• Fig. 35 Small molecule innovator API CDMO market: Customer type movement analysis
• Fig. 36 Pharmaceutical small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 37 Small pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 38 Medium pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Large pharmaceutical customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Biotechnology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Small biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Medium biotechnology customer in small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Large biotechnology customer in small molecule molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Small molecule innovator API CDMO market: Therapeutic area outlook and key takeaways
• Fig. 45 Small molecule innovator API CDMO market: Therapeutic area movement analysis
• Fig. 46 Cardiovascular diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Oncology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Respiratory disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Neurology small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Metabolic disorders small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Infectious diseases small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Others small molecule innovator API CDMO market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Regional market: Key takeaways
• Fig. 54 Regional outlook, 2023 & 2030
• Fig. 55 Regional outlook, 2023 & 2030
• Fig. 56 North America small molecule innovator API CDMO market, 2018 - 2030 (USD Million)
• Fig. 57 Key country dynamics
• Fig. 58 U.S. small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 59 Key country dynamics
• Fig. 60 Canada small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 61 Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 62 Key country dynamics
• Fig. 63 UK small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 64 Key country dynamics
• Fig. 65 Germany small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 66 Key country dynamics
• Fig. 67 France small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 68 Key country dynamics
• Fig. 69 Italy small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 70 Key country dynamics
• Fig. 71 Spain small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 72 Key country dynamics
• Fig. 73 Denmark small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 74 Key country dynamics
• Fig. 75 Sweden small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 76 Key country dynamics
• Fig. 77 Norway small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 78 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 79 MEA small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 80 Key country dynamics
• Fig. 81 South Africa small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 82 Key country dynamics
• Fig. 83 Saudi Arabia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 84 Key country dynamics
• Fig. 85 Clinical trial authorization process UAE
• Fig. 86 UAE small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 87 Key country dynamics
• Fig. 88 Regulatory framework: South Africa
• Fig. 89 Kuwait small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 90 Key country dynamics
• Fig. 91 Israel small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 92 Rest of Europe small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 93 Asia Pacific small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 94 Key country dynamics
• Fig. 95 China small molecule innovator API CDMO estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 96 Key country dynamics
• Fig. 97 Regulatory bodies in India involved in pharmaceutical regulations
• Fig. 98 India small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 99 Key country dynamics
• Fig. 100 Clinical trial authorization process in Japan
• Fig. 101 Clinical research of medical products in Japan
• Fig. 102 Japan small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 103 Key country dynamics
• Fig. 104 Australia small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 105 Key country dynamics
• Fig. 106 Clinical trial approval process in South Korea
• Fig. 107 South Korea small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 108 Key country dynamics
• Fig. 109 Thailand small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 110 Key country dynamics
• Fig. 111 Taiwan small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 112 Rest of APAC small molecule innovator API CDMO Market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 113 Key country dynamics
• Fig. 114 Brazil small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 115 Key country dynamics
• Fig. 116 Mexico small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 117 Key country dynamics
• Fig. 118 Argentina pharmaceuticals registration details
• Fig. 119 Argentina small molecule innovator API CDMO market estimates and forecasts, 2018 - 2030 (USD Million)
• Fig. 120 Market participant categorization
• Fig. 121 Heat map analysis
• Fig. 122 Market participant categorization

Small Molecule Innovator API CDMO Market Growth & Trends:

The global small molecule innovator API CDMO market size is expected to reach USD 47.14 billion by 2030, registering a CAGR of 6.53% from 2024 to 2030, according to a new report by Grand View Research, Inc. A growing outsourcing trend among pharmaceutical companies, increasing demand for small molecule drugs, and a surge in the number of clinical trials are anticipated to influence the market positively. The growing utilization of CDMOs in the pharmaceutical sector stems from various reasons, with cost-effectiveness as the prominent factor. Outsourcing emerges as an efficient strategy for pharmaceutical firms to reduce expenses by sidestepping the necessity for costly infrastructure and equipment investments. CDMOs offer the requisite expertise and infrastructure to deliver drug development and manufacturing services in a financially prudent manner.

Furthermore, enhanced efficiency serves as another pivotal driver for pharmaceutical outsourcing. With mounting pressure on pharmaceutical companies to expedite the introduction of new drugs to the market, outsourcing emerges as a solution to accelerate the drug development process. Leveraging their expertise, experience, and cutting-edge equipment, CDMOs facilitate the swift & efficient production of high-quality drugs, enabling pharmaceutical firms to adhere to their development schedules. In addition, several pharmaceutical companies prefer CDMOs to access advanced infrastructure and expertise due to the increasing influx of novel therapies & orphan drugs and higher returns on approved products. Moreover, continuous technological advancements among CDMOs offer innovative small molecule APIs to meet the growing demands for innovation, efficiency, and regulatory compliance in the healthcare industry.

The adoption of advanced technologies by companies enhances drug development, manufacturing processes, and productivity. The increasing demand for new small molecule innovator API in the pharmaceutical industry is encouraging commercial CDMOs to expand their capabilities, which is expected to boost market growth. For instance, in August 2023, Astex announced a research collaboration & license agreement with MSD to classify small molecule candidates with tumor suppressor proteins for cancer treatment. Under the agreement, the company will use its fragment-based drug discovery platform to develop compounds and provide MSD with main compounds for preclinical development & optimization.

Small Molecule Innovator API CDMO Market Report Highlights:

• The clinical stage type segment dominated the market with a share of 54.68% in 2023. Growth in the segment can be attributed to the rising clinical trial (phase I-III) activities for diverse formulations, growing small molecule development pipeline, increasing availability of specialized expertise, timesaving & cost-efficiency for investigational drugs, and innovations. Moreover, rising funding for drug development is propelling segment growth
• Based on the customer type, the pharmaceutical segment held the largest share in 2023 due to rapid advancements in pharmaceutical R&D for the development of advanced drugs. In addition, advancements in various therapies have shifted pharmaceutical companies' focus on CDMOs to developing novel small molecule innovator API drugs to treat numerous diseases
• The oncology therapeutic area segment dominated the market and accounted for a share of 42.25% in 2023. The segment growth is driven by the increasing prevalence of cancer globally. In addition, growing demand for innovative small molecule innovator APIs, advancements in targeted therapies, and demand for oncology drugs innovations are the factors driving the oncology segment
• Asia Pacific dominated the market with a share of 41.53% in 2023 due to increasing prevalence of chronic diseases, demand for small molecule APIs & CDMO services, and improving healthcare infrastructure

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
  • 1.1.1. Regional Scope
  • 1.1.2. Estimates and Forecast Timeline
• 1.2. Research Methodology
• 1.3. Information Procurement
  • 1.3.1. Purchased Database
  • 1.3.2. GVR's Internal Database
  • 1.3.3. Secondary Sources
  • 1.3.4. Primary Research
  • 1.3.5. Details of Primary Research
• 1.4. Information or Data Analysis
  • 1.4.1. Data Analysis Models
• 1.5. Market Formulation & Validation
  • 1.5.1. Region Wise Market: Base Estimates
  • 1.5.2. Global Market: CAGR Calculation
• 1.6. Model Details
  • 1.6.1. Commodity Flow Analysis (Model 1)
  • 1.6.2. Value-Chain-Based Sizing & Forecasting (Model 2)
  • 1.6.3. QFD Model Sizing & Forecasting (Model 3)
  • 1.6.4. Bottom-Up Approach (Model 4)
• 1.7. Market Definitions
• 1.8. List of Secondary Sources
• 1.9. List of Abbreviations
• 1.10. Objectives
  • 1.10.1. Objective - 1
  • 1.10.2. Objective - 2
  • 1.10.3. Objective - 3
  • 1.10.4. Objective - 4

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Small Molecule Innovator API CDMO Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent market outlook
  • 3.1.2. Ancillary Market outlook
• 3.2. Market Dynamics
  • 3.2.1. Market driver analysis
    • 3.2.1.1. Increasing Demand for Small Molecule Drugs
    • 3.2.1.2. Increasing Outsourcing Trends Among Pharmaceutical Companies
    • 3.2.1.3. Surge in Number of Clinical Trials
  • 3.2.2. Market restraint analysis
    • 3.2.2.1. Compliance Issues While Outsourcing
    • 3.2.2.2. Changing Scenarios in Developing Economies
• 3.3. Technology Landscape
  • 3.3.1. Integration Of Ai In Small Molecule Innovator API CDMO Market
    • 3.3.1.1. Current Dynamics and Future Trends
    • 3.3.1.1.1. Drug Discovery and Design
    • 3.3.1.1.2. AI-Assisted Drug API Synthesis
    • 3.3.1.1.3. Process Optimization
    • 3.3.1.1.4. Supply Chain Management
    • 3.3.1.1.5. Clinical Trial Optimization
    • 3.3.1.1.6. Regulatory Compliance
• 3.4. Total Number of Clinical Trials by Phase & Region (2021 - 2023)
  • 3.4.1. Total Number of Clinical Trials by Phase (2021 - 2023)
  • 3.4.2. Total Number of Clinical Trials by Region (2021 - 2023)
    • 3.4.2.1. Percentage of Clinical Trials by Major Countries in North America:
    • 3.4.2.2. Percentage of Clinical Trials by Major Countries in Europe:
    • 3.4.2.3. Percentage of Clinical Trials by Major Countries in Asia Pacific:
    • 3.4.2.4. Percentage of Clinical Trials by Major Countries in Latin America:
    • 3.4.2.5. Percentage of Clinical Trials by Major Countries in the Middle East & Africa:
  • 3.4.3. Total Number of Clinical Trials by Therapeutic Area (2021 - 2023)
• 3.5. Small Molecule Innovator API CDMO Market: Analysis Tools
  • 3.5.1. Porter's Five Forces Analysis
  • 3.5.2. PESTEL Analysis
• 3.6. Impact of COVID-19 on Small Molecule Innovator CDMO Market
• 3.7. COVID-19 Impact Analysis

Chapter 4. Small Molecule Innovator API CDMO Market: Stage Type Estimates & Trend Analysis

• 4.1. Segment Dashboard
• 4.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
• 4.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Stage Type, 2018 to 2030 (USD Million)
  • 4.3.1. Preclinical
    • 4.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.3.2. Clinical
    • 4.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2.2. Phase I
    • 4.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2.3. Phase II
    • 4.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 4.3.2.4. Phase III
    • 4.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 4.3.3. Commercial
    • 4.3.3.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 5. Small Molecule Innovator API CDMO Market: Customer Type Estimates & Trend Analysis

• 5.1. Segment Dashboard
• 5.2. Global Small Molecule Innovator API CDMO Market Movement Analysis
• 5.3. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Customer Type, 2018 to 2030 (USD Million)
  • 5.3.1. Pharmaceutical
    • 5.3.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.1.2. Small
    • 5.3.1.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.1.3. Medium
    • 5.3.1.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.1.4. Large
    • 5.3.1.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 5.3.2. Biotechnology
    • 5.3.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2.2. Small
    • 5.3.2.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2.3. Medium
    • 5.3.2.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
    • 5.3.2.4. Large
    • 5.3.2.4.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 6. Small Molecule Innovator API CDMO Market: Therapeutic Area Estimates & Trend Analysis

• 6.1. Definitions and Scope
  • 6.1.1. Cardiovascular Diseases
  • 6.1.2. Oncology
  • 6.1.3. Respiratory Disorders
  • 6.1.4. Neurology
  • 6.1.5. Metabolic Disorders
  • 6.1.6. Infectious Diseases
  • 6.1.7. Others
• 6.2. Therapeutic Area Market Share, 2023 & 2030
• 6.3. Segment Dashboard
• 6.4. Global Small Molecule Innovator API CDMO Market Movement Analysis
• 6.5. Global Small Molecule Innovator API CDMO Market Size & Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Million)
  • 6.5.1. Cardiovascular Diseases
    • 6.5.1.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.2. Oncology
    • 6.5.2.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.3. Respiratory Disorders
    • 6.5.3.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.4. Neurology
    • 6.5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.5. Metabolic Disorders
    • 6.5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.6. Infectious Diseases
    • 6.5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
  • 6.5.7. Others
    • 6.5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)

Chapter 7. Small Molecule Innovator API CDMO Market: Regional Estimates & Trend Analysis by Product, Workflow, & Application

• 7.1. Regional Market Dashboard
• 7.2. Global Regional Market Snapshot
• 7.3. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
• 7.4. North America
  • 7.4.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Competitive Scenario
    • 7.4.2.3. Regulatory Scenario
    • 7.4.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Competitive Scenario
    • 7.4.3.3. Regulatory Scenario
    • 7.4.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
• 7.5. Europe
  • 7.5.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Competitive Scenario
    • 7.5.2.3. Regulatory Scenario
    • 7.5.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Competitive Scenario
    • 7.5.3.3. Regulatory Scenario
    • 7.5.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Competitive Scenario
    • 7.5.4.3. Regulatory Scenario
    • 7.5.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Competitive Scenario
    • 7.5.5.3. Regulatory Scenario
    • 7.5.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Competitive Scenario
    • 7.5.6.3. Regulatory Scenario
    • 7.5.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Competitive Scenario
    • 7.5.7.3. Regulatory Scenario
    • 7.5.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Competitive Scenario
    • 7.5.8.3. Regulatory Scenario
    • 7.5.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Competitive Scenario
    • 7.5.9.3. Regulatory Scenario
    • 7.5.9.4. Market estimates and forecast, 2018 - 2030 (USD Million)
• 7.6. Asia Pacific
  • 7.6.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.2. China
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Competitive Scenario
    • 7.6.2.3. Regulatory Scenario
    • 7.6.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.3. Japan
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Competitive Scenario
    • 7.6.3.3. Regulatory Scenario
    • 7.6.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Competitive Scenario
    • 7.6.4.3. Regulatory Scenario
    • 7.6.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Competitive Scenario
    • 7.6.5.3. Regulatory Scenario
    • 7.6.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Competitive Scenario
    • 7.6.6.3. Regulatory Scenario
    • 7.6.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Competitive Scenario
    • 7.6.7.3. Regulatory Scenario
    • 7.6.7.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.6.8. Taiwan
    • 7.6.8.1. Key Country Dynamics
    • 7.6.8.2. Competitive Scenario
    • 7.6.8.3. Regulatory Scenario
    • 7.6.8.4. Market estimates and forecast, 2018 - 2030 (USD Million)
• 7.7. Latin America
  • 7.7.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Competitive Scenario
    • 7.7.2.3. Regulatory Scenario
    • 7.7.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.3. Mexico
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Competitive Scenario
    • 7.7.3.3. Regulatory Scenario
    • 7.7.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.7.4. Argentina
    • 7.7.4.1. Key Country Dynamics
    • 7.7.4.2. Competitive Scenario
    • 7.7.4.3. Regulatory Scenario
    • 7.7.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
• 7.8. MEA
  • 7.8.1. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Competitive Scenario
    • 7.8.2.3. Regulatory Scenario
    • 7.8.2.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Competitive Scenario
    • 7.8.3.3. Regulatory Scenario
    • 7.8.3.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Competitive Scenario
    • 7.8.4.3. Regulatory Scenario
    • 7.8.4.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Competitive Scenario
    • 7.8.5.3. Regulatory Scenario
    • 7.8.5.4. Market estimates and forecast, 2018 - 2030 (USD Million)
  • 7.8.6. Israel
    • 7.8.6.1. Key Country Dynamics
    • 7.8.6.2. Competitive Scenario
    • 7.8.6.3. Regulatory Scenario
    • 7.8.6.4. Market estimates and forecast, 2018 - 2030 (USD Million)

Chapter 8. Competitive Landscape

• 8.1. Market Participant Categorization
• 8.2. Service Heat Map Analysis (a comparative analysis of the players together)
• 8.3. Company Profiles
• 8.4. Company Profiles
  • 8.4.1. Strategy Mapping
  • 8.4.2. Expansion
  • 8.4.3. Partnerships
  • 8.4.4. Acquisitions
• 8.5. Vendor Landscape
  • 8.5.1. Key company market share analysis, 2023
  • 8.5.2. Lonza Group Ltd.
    • 8.5.2.1. Company overview
    • 8.5.2.2. Financial performance
    • 8.5.2.3. Product/service benchmarking
    • 8.5.2.4. Strategic initiatives
  • 8.5.3. Novo Holdings (Catalent, Inc.)
    • 8.5.3.1. Company overview
    • 8.5.3.2. Financial performance
    • 8.5.3.3. Product/service benchmarking
    • 8.5.3.4. Strategic initiatives
  • 8.5.4. Thermo Fisher Scientific, Inc.
    • 8.5.4.1. Company overview
    • 8.5.4.2. Financial performance
    • 8.5.4.3. Product/service benchmarking
    • 8.5.4.4. Strategic initiatives
  • 8.5.5. Siegfried Holding AG
    • 8.5.5.1. Company overview
    • 8.5.5.2. Financial performance
    • 8.5.5.3. Product/service benchmarking
    • 8.5.5.4. Strategic initiatives
  • 8.5.6. Recipharm AB
    • 8.5.6.1. Company overview
    • 8.5.6.2. Financial performance
    • 8.5.6.3. Product/service benchmarking
    • 8.5.6.4. Strategic initiatives
  • 8.5.7. CordenPharma International
    • 8.5.7.1. Company overview
    • 8.5.7.2. Financial performance
    • 8.5.7.3. Product/service benchmarking
    • 8.5.7.4. Strategic initiatives
  • 8.5.8. Samsung Biologics
    • 8.5.8.1. Company overview
    • 8.5.8.2. Financial performance
    • 8.5.8.3. Product/service benchmarking
    • 8.5.8.4. Strategic initiatives
  • 8.5.9. Labcorp
    • 8.5.9.1. Company overview
    • 8.5.9.2. Financial performance
    • 8.5.9.3. Product/service benchmarking
    • 8.5.9.4. Strategic initiatives
  • 8.5.10. Ajinomoto Bio-Pharma Services
    • 8.5.10.1. Company overview
    • 8.5.10.2. Financial performance
    • 8.5.10.3. Product/service benchmarking
    • 8.5.10.4. Strategic initiatives
  • 8.5.11. Piramal Pharma Solutions
    • 8.5.11.1. Company overview
    • 8.5.11.2. Financial performance
    • 8.5.11.3. Product/service benchmarking
    • 8.5.11.4. Strategic initiatives
  • 8.5.12. Jubilant Life Sciences (Jubilant Biosys Limited)
    • 8.5.12.1. Company overview
    • 8.5.12.2. Financial performance
    • 8.5.12.3. Product/service benchmarking
    • 8.5.12.4. Strategic initiatives
  • 8.5.13. WuXi AppTec Co., Ltd.
    • 8.5.13.1. Company overview
    • 8.5.13.2. Financial performance
    • 8.5.13.3. Product/service benchmarking
    • 8.5.13.4. Strategic initiatives